Compounded 17-hydroxyprogesterone caproate is an inexpensive and safe alternative to the FDA-approved product
| Autor: | Samuel Parry, Arnold Cohen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Pediatrics business.industry Obstetrics and Gynecology First year of life Institute of medicine Uterine Monitoring Asymptomatic medicine.anatomical_structure Transvaginal ultrasound medicine medicine.symptom Intensive care medicine business Cervix Hydroxyprogesterone caproate health care economics and organizations Preterm delivery medicine.drug |
| Zdroj: | American Journal of Obstetrics and Gynecology. 210:12-13 |
| ISSN: | 0002-9378 |
| DOI: | 10.1016/j.ajog.2013.11.019 |
| Popis: | Prematurity continues to be the major source of neonatal morbidity and mortality. Efforts to decrease the risk of prematurity in the past have focused on preventing contractions with tocolytics, early identification of contractions with home uterine monitoring, and predicting preterm delivery through history and biochemical evaluations. The Institute of Medicine estimated in 2005 that the average direct medical care costs for a preterm infant in the United States is $33,200, with the majority (85%) of this cost occurring in the first year of life. 1 The cost per infant increases to $51,600 when maternal medical care costs ($3800), early intervention costs ($1203), special education costs ($2150), and lost household productivity costs ($11,215) are considered. The only markers for increased risk of preterm delivery that have reasonable positive predictive values in the asymptomatic patient are a history of preterm delivery and the finding on transvaginal ultrasound of a shortened cervix |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect